Alembic Pharmaceuticals Ltd., a pharmaceutical company engaged in manufacturing pharmaceutical products, substances, and intermediates, is recognised as a market leader in India for anti-infective drugs in the macrolides segment. The company was incorporated in 1907, with its headquarters in Vadodara. For FY 2021-2022, Alembic Pharmaceuticals Ltd. recorded a total revenue of Rs 5,356.25 crore, down 0.87% from the previous financial year, 2020-2021. On 10 October 2022, the company’s market capitalisation stood at Rs 12,014 crore.
The company is listed on the Bombay Stock Exchange with the code 533573, and on the National Stock Exchange with the code APLLTD.
Alembic Pharmaceuticals Ltd. manufactures and markets Indian formulations, international generics, and active pharmaceutical ingredients across the globe. During the quarter that ended in June 2022, the company reported a loss of Rs 65.88 crore after three consecutive quarters of profits.
The company’s shareholding pattern at the end of the June 2022 quarter represented a promoter stake of 69.61%, a foreign institutional investor stake of 5.94%, a domestic institutional investor stake of 12.15%, and a public stake of 12.3%. The leading promoter was Nirayu Limited having a 35.63% stake. During the same quarter, the company’s mutual fund holdings decreased from 5.18% to 5.01%, and foreign institutional investor holdings also decreased from 6.02% to 5.94%.
Mr Chirayu Amin is the company’s chairman and CEO. Mr Praniv Amin and Mr Shaunak Amin are the managing directors. The other members of the leadership team include Mr Raj Kumar Baheti, Mr Pranav Parikh, Mr K G Ramanathan, Mr Ashok Barat, Mr Paresh Saraiya, and Dr Archana Hingorani. The company’s auditors include K C Mehta & Co and K S Aiyar & Co. As of 30 June 2022, Alembic Pharmaceuticals Ltd.’s total outstanding shares were 19.66 crores.
On 10 October 2022, Alembic Pharmaceuticals Ltd.’s share price closed at Rs 610.30 on BSE and at Rs 611.25 on NSE. The company’s 52-week high share price was Rs 864.05, and the 52-week low share price was Rs 577.75.
As of September 2022, Union Liquid Fund had a 5.23% stake in Alembic Pharmaceuticals Ltd. The other mutual fund holdings include Kotak Small Cap Fund, DSP Midcap Fund, and DSP Healthcare Fund, with a 2.10%, 1.63%, and 1.39% stake, respectively.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose
Stock Screener (i-Lens)
ICICIdirect Alembic Pharmaceuticals Ltd FAQ 
